Shopping Cart

Your shopping cart is currently empty

Cisatracurium besylate

Name: Cisatracurium besylate
Brand: TargetMol
SKU: T1459
Price: 39 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

😃Good

Catalog No. T1459Cas No. 96946-42-8

Alias 51W89

Cisatracurium besylate (51W89) is a nondepolarizing skeletal muscle relaxant intended for intravenous administration.

Cisatracurium besylate

Copy Product Info

😃Good

Purity: 99.85%

Catalog No. T1459Alias 51W89Cas No. 96946-42-8

Cisatracurium besylate (51W89) is a nondepolarizing skeletal muscle relaxant intended for intravenous administration.

Pack Size	Price	USA Warehouse	Global Warehouse
10 mg	$39	-	In Stock
25 mg	$64	-	In Stock
50 mg	$113	-	In Stock
100 mg	$189	-	In Stock
200 mg	$278	-	In Stock
500 mg	$475	-	In Stock
1 mL x 10 mM (in DMSO)	$55	-	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.85%

Resource Download

COA HNMR

Product Introduction

Cisatracurium besylate AI Summary

Cisatracurium besylate demonstrates multiple bioactivities, including modulation of Lamin A splicing with a potency of 125.9 nM, activation and inhibition of Cytochrome P450 3A4 both with a potency of 10000.0 nM, and activity within the Cytochrome panel assay with an AC50 value of 10000.0 nM. Additionally, it inhibits the malarial parasite plastid with a potency of 2031.5 nM and interacts with the S16 Schwann cell PMP22 intronic element firefly luciferase assay with a potency of 15471.9 nM. Importantly, Cisatracurium besylate shows no induction of drug-induced liver injury in human cells, suggesting a lack of liver toxicity. Furthermore, it inhibits cell viability in Vero E6 cells infected with SARS-CoV-2 (strain BavPat1) at a multiplicity of infection (MOI) of 0.002 after 72 hours, with an inhibition index of 1.338, indicating higher activity compared to the arbidol control..

Note: Summary generated by AI. Data source: ChEMBL

Bioactivity

Description	Cisatracurium besylate (51W89) is a nondepolarizing skeletal muscle relaxant intended for intravenous administration.
Synonyms	51W89

Chemical Properties

Molecular Weight	1243.48
Formula	C₅₃H₇₂N₂O₁₂·2C₆H₅O₃S
Cas No.	96946-42-8
Smiles	C[N@@+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C=C3)OC)OC)OC)OC)CCC(=O)OCCCCCOC(=O)CC[N@+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C=C6)OC)OC)OC)OC)C.C1=CC=C(C=C1)S(=O)(=O)[O-].C1=CC=C(C=C1)S(=O)(=O)[O-]
Relative Density.	no data available

Storage & Solubility Information

Storage

store at low temperature,keep away from direct sunlight | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

Ethanol: 229 mg/mL (184.16 mM), Sonication is recommended.

DMSO: 229 mg/mL (184.16 mM), Sonication is recommended.

H2O: 43 mg/mL (34.58 mM), Sonication is recommended.

Solution Preparation Table

H2O/Ethanol/DMSO

	1mg	5mg	10mg	50mg
1 mM	0.8042 mL	4.0210 mL	8.0419 mL	40.2097 mL
5 mM	0.1608 mL	0.8042 mL	1.6084 mL	8.0419 mL
10 mM	0.0804 mL	0.4021 mL	0.8042 mL	4.0210 mL
20 mM	0.0402 mL	0.2010 mL	0.4021 mL	2.0105 mL

Ethanol/DMSO

	1mg	5mg	10mg	50mg
50 mM	0.0161 mL	0.0804 mL	0.1608 mL	0.8042 mL
100 mM	0.0080 mL	0.0402 mL	0.0804 mL	0.4021 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc